TITLE

Regimen Simplification to Atazanavir-Ritonavir Alone as Maintenance Antiretroviral Therapy: Final 48-Week Clinical and Virologic Outcomes

AUTHOR(S)
Wilkin, Timothy J.; McKinnon, John E.; DiRienzo, A. Gregory; Mollan, Katie; Fletcher, Courtney V.; Margolis, David M.; Bastow, Barbara; Thal, Gary; Woodward, William; Godfrey, Catherine; Wiegand, Ann; Maldarelli, Frank; Palmer, Sarah; Coffin, John M.; Mellors, John W.; Swindells, Susan
PUB. DATE
March 2009
SOURCE
Journal of Infectious Diseases;3/15/2009, Vol. 199 Issue 6, p866
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Simplified maintenance therapy with ritonavir-boosted atazanavir (ATV/RTV) alone is attractive because of nucleoside reverse-transcriptase inhibitor (NRTI)-sparing benefits, low pill burden, once-daily dosage, and safety. Methods. Subjects with virologic suppression after ⩾48 weeks of initial antiretroviral therapy with 2 NRTIs and a protease inhibitor (PI) were enrolled. Subjects switched to ATV/RTV at entry and discontinued NRTIs after 6 weeks. The primary end point was time to virologic failure (confirmed HIV-1 RNA level ⩾200 copies/mL). Drug resistance at virologic failure was evaluated by standard genotyping and single-genome sequencing (SGS). Residual viremia (1.1-49 copies/mL) was measured by single-copy assay. Results. Thirty-four subjects simplified to ATV/RTV alone, of whom 30 (88%) did not experience virologic failure by 48 weeks after simplification. Residual viremia did not change significantly after NRTI discontinuation among those without virologic failure but did increase 4-12 weeks before confirmed virologic failure. No major PI-resistance mutations were identified at virologic failure by standard genotyping or SGS. Conclusions. In this pilot study, simplified maintenance therapy with ATV/RTV alone maintained viral suppression in most subjects through 48 weeks. PI resistance was not detected among subjects experiencing virologic failure. Larger, randomized trials are warranted to further define the efficacy and safety of this strategy.
ACCESSION #
37035049

 

Related Articles

  • Design Strategies of Novel NNRTIs to Overcome Drug Resistance. Peng Zhan; Xinyong Liu; Zhenyu Li; Pannecouque, Christophe; De Clercq, Erik // Current Medicinal Chemistry;Oct2009, Vol. 16 Issue 29, p3903 

    Nonnucleoside reverse transcriptase inhibitors (NNRTIs) are very potent and most promising anti-AIDS drugs that specifically inhibit HIV-1 reverse transcriptase (RT). However, to a great extent, the efficacy of NNRTI drugs is impaired by rapid emergence of drug-resistance mutations. Fortunately,...

  • The Antiviral Activity, Mechanism of Action, Clinical Significance and Resistance of Abacavir in the Treatment of Pediatric AIDS. Melroy, Joel; Nair, Vasu // Current Pharmaceutical Design;Nov2005, Vol. 11 Issue 29, p3847 

    The novel carbocyclic nucleoside, abacavir, is metabolized in cells to carbovir triphosphate which is a potent inhibitor of HIV reverse transcriptase (Ki 0.021 μM with calf thymus DNA template primer). Abacavir exhibits potent in vitro antiviral activity against wild-type HIV-1 (IC50 4.0...

  • Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors and Prevalence of HIV Type 1 Non-B Subtypes Are Increasing among Persons with Recent Infection in Spain. de Mendoza, Carmen; Rodriguez, Carmen; Colomina, Javier; Tuset, Concepción; Garcia, Federico; Eiros, José M.; Corral, Angelica; Leiva, Pilar; Aguero, Jesús; Torre-Cisneros, Julián; Pedreira, José; Viciana, Isabel; del Romero, Jorge; Saez, Ana; de Lejarazu, Raúl Ortiz; Soriano, Vincent // Clinical Infectious Diseases;11/1/2005, Vol. 41 Issue 9, p1350 

    The prevalence of drug resistance mutations was 12.1% among 198 persons who experienced human immunodeficiency virus (HIV) seroconversion identified in Spain during 1997-2004. There was a significant increase of K103N and of non-B subtypes over time. Transmission of HIV infection around the time...

  • The Influence of Natural Substrates and Inhibitors on the Nucleotide- Dependent Excision Activity of HIV-1 Reverse Transcriptase in the Infected Cell. Smith, Anthony James; Scott, Walter Alvin // Current Pharmaceutical Design;Jun2006, Vol. 12 Issue 15, p1827 

    Human immunodeficiency virus type 1 resistance to nucleoside reverse transcriptase inhibitors such as 3'- azido-2', 3'-dideoxythymidine (AZT) can arise through mutations in the coding region of reverse transcriptase (RT) that enhance the enzyme's ability to remove the drug after it has been...

  • Drug-Resistant HIV Infection among Drug-Naive Patients in Israel. Grossman, Z.; Lorber, M.; Maayan, S.; Bar-Yacov, N.; Levy, I.; Averbuch, D.; Istomin, V.; Chowers, M.; Sthoeger, Z.; Ram, D.; Rudich, H.; Mileguir, F.; Pavel, R.; Almaliach, R.; Schlaeffer, F.; Kra-Oz, Z.; Mendelson, E.; Schapiro, J. M.; Riesenberg, K. // Clinical Infectious Diseases;1/15/2005, Vol. 40 Issue 2, p294 

    Background. In Israel, <0.0 6% of the general population is infected with human immunodeficiency virus (HIV), with a much higher prevalence among specific groups. These groups are distinguished demographically by risk behavior category and by virus subtype. We investigated transmission of drug...

  • Improved Interpretation of Genotypic Changes in the HIV-1 Reverse Transcriptase Coding Region That Determine the Virological Response to Didanosine. De Luca, Andrea; Di Giambenedetto, Simona; Trotta, Maria Paola; Colafigli, Manuela; Prosperi, Mattia; Ruiz, Lidia; Baxter, John; Clevenbergh, Philippe; Cauda, Roberto; Perno, Carlo-Federico; Antinori, Andrea // Journal of Infectious Diseases;12/1/2007, Vol. 196 Issue 11, p1645 

    Background. Consensus on the interpretation of mutations in the human immunodeficiency virus (HIV)-1 reverse transcriptase (RT) gene that predict the response to didanosine treatment is needed. Methods. Baseline HIV-1 RT genotypes and 12-week virological outcomes for patients undergoing...

  • The ''Connection'' Between HIV Drug Resistance and RNase H. Delviks-Frankenberry, Krista A.; Nikolenko, Galina N.; Pathak, Vinay K. // Viruses (1999-4915);Jul2010, Vol. 2 Issue 7, p1476 

    Currently, nucleoside reverse transcriptase inhibitors (NRTIs) and nonnucleoside reverse transcriptase inhibitors (NNRTIs) are two classes of antiretroviral agents that are approved for treatment of HIV-1 infection. Since both NRTIs and NNRTIs target the polymerase (pol) domain of reverse...

  • How to Start Antiretroviral Therapy? Horster, S.; Goebel, F.-D. // Infection;Jun2004, Vol. 32 Issue 3, p184 

    The article presents information about antiretroviral therapy (ART). Whenever started, ART should undoubtedly provide suppression of HIV replication, that is, plasma HIV-RNA below limit of detection for the longest time period possible. First attempts to meet this demand had been made with...

  • The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco. Bakhouch, Khadija; Oulad-Lahcen, Ahd; Bensghir, Rajae; Blaghen, Mohamed; Elfilali, Kamal Marhoum; Ezzikouri, Sayeh; Abidi, Omar; Hassar, Mohamed; Wakrim, Lahcen // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 5, p380 

    Background: The widespread use of antiretroviral agents and the growing occurrence of HIV-1 strains resistant to these drugs have given rise to serious concerns regarding the transmission of resistant viruses to newly infected persons, which may reduce the efficacy of a first-line antiretroviral...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics